Sugi Predict

Sugi Predict / Compounds / SCHEMBL376711

SCHEMBL376711

SCHEMBL376711

C=CCN(CC=O)C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.37
▸ CA14 Q9ULX7 1/20 0.36
▸ DPP4 P27487 1/20 0.36
▸ HDAC6 Q9UBN7 2/20 0.34
▸ HDAC1 Q13547 1/20 0.33
▸ HDAC2 Q92769 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.32
▸ MAPT P10636 1/20 0.31
▸ NFKB1 P19838 1/20 0.30
▸ NFKB2 Q00653 1/20 0.30
▸ RELA Q04206 1/20 0.30
▸ LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL956549 0.93 ALDH1A1 (0.42) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL111602 0.91 CA14 (0.40) CA14HDAC6HDAC1HDAC2NFKB1
SCHEMBL15604295 0.84 ALDH1A1 (0.36) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL3178526 0.84 ALDH1A1 (0.38) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL21700032 0.82 ALDH1A1 (0.33) ALDH1A1DPP4
SCHEMBL3020149 0.82 CA14 (0.49) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL1462541 0.81 CA14 (0.37) CA14HDAC6HDAC1HDAC2L3MBTL1
SCHEMBL15549015 0.81 ALDH1A1 (0.34) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL15549014 0.81 ALDH1A1 (0.34) ALDH1A1CA14DPP4HDAC6HDAC1
SCHEMBL23540791 0.81 ALDH1A1 (0.36) ALDH1A1CA14DPP4HDAC6HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2025-10-09 — — US disclosed
EP-4536653-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME Eisai R&D Management Co., Ltd. (JP) 2025-04-16 — — EP disclosed
EP-3833672-B1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE SRL (IT) 2024-09-18 — — EP disclosed
CN-113272309-B Tricyclic inhibitors of hepatitis b virus 圣拉斐尔医院有限公司 2024-02-23 — — CN disclosed
WO-2023239906-A2 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME EISAI R&D MANAGEMENT CO., LTD. (JP) 2023-12-14 — — WO disclosed
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS ANTIOS THERAPEUTICS INC (US) 2023-03-09 — — US disclosed
US-11504382-B2 Tricyclic inhibitors of Hepatitis B virus Antios Therapeutics, Inc. (US) 2022-11-22 — — US disclosed
US-20220110943-A1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS OSPEDALE SAN RAFFAELE S.R.L. (IT) 2022-04-14 — — US disclosed
EP-3193604-B1 SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS EPIZYME INC (US) 2021-06-16 — — EP disclosed
EP-3193604-B1 SUBSTITUTED N-(PYRROLIDIN-3-YL)ISOXAZOLE-3-CARBOXAMIDE COMPOUNDS EPIZYME INC (US) 2021-06-16 — — EP disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC (US) 2011-06-16 — — US disclosed
US-7662816-B2 Cyclic amine BACE-1 inhibitors having a benzamide substituent SCHERING CORPORATION (US) 2010-02-16 — — US disclosed
WO-2010016005-A1 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS PFIZER INC. (US) 2010-02-11 — — WO disclosed
EP-1660443-B1 CYCLIC AMINE BACE-1 INHIBITORS HAVING A BENZAMIDE SUBSTITUENT SCHERING CORP (US) 2009-03-04 — — EP disclosed
US-20050119227-A1 Cyclic amine bace-1 inhibitors having a benzamide substituent SCHERING CORPORATION 2005-06-02 — — US disclosed
US-5241076-A 1,4-diazatricyclo [6.3.0.0]undecanes BAYER AKTIENGESELLSCHAFT (DE) 1993-08-31 — — US disclosed
US-5177210-A Preparation of 2,7-diazabicyclo(3.3.0)octanes BAYER AKTIENGESELLSCHAFT (DE) 1993-01-05 — — US disclosed
US-5071999-A Preparation of 2,7-diazabicyclo[3.3.0]octanes BAYER AKTIENGESELLSCHAFT (DE) 1991-12-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11504382-B2 Tricyclic inhibitors of Hepatitis B virus HAVCR2, NR1H4, HCCS ALDH1A1 1104/4885CA14 3055/4885DPP4 558/4885
US-20220110943-A1 TRICYCLIC INHIBITORS OF HEPATITIS B VIRUS HAVCR2, NR1H4, HCCS ALDH1A1 1104/4885CA14 3055/4885DPP4 558/4885
US-20050119227-A1 Cyclic amine bace-1 inhibitors having a benzamide substituent BACE1, BACE2, BCHE ALDH1A1 1302/4885CA14 2549/4885DPP4 2211/4885
US-20250313574-A1 SIALIC ACID DERIVATIVES AND METHODS OF USING SAME NEU1, NEU2, NEU4 ALDH1A1 474/4885CA14 62/4885DPP4 339/4885
US-20230076319-A1 INHIBITORS OF HEPATITIS B VIRUS HAVCR2, HDGF, SLC10A1 ALDH1A1 1035/4885CA14 2600/4885DPP4 343/4885
US-20110144084-A1 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS CHKA, CSNK1A1, CHKB ALDH1A1 2651/4885CA14 2767/4885DPP4 1731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.